Regeneron Pharmaceuticals, Inc. REGN
NASDAQ · Healthcare · Biotechnology
$920.69
Close on Fri, 20 Nov 2026 · market value $95.2B
What the price is betting on
Below its recordAt $921, the price assumes revenue grows about 0% a year for five years, from $16.9B to about $16.9B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.5% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than REGN? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$1,312
Base
$1,661
Bull
$2,099
Today $921
- Bear $1,312. Cash flow grows 6% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $1,661. Cash flow grows 11% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $2,099. Cash flow grows 15% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$16.9B$18.8B, on the path
- FY2027$16.9B$20.1B, on the path
- FY2028$16.9B$21.6B, on the path
- FY2029$16.9B$23.3B, on the path
- FY2030$16.9B$24.8B, on the path
Each year's revenue at 0% growth from $16.9B in the 12 months to September 2026.
At a glance
Healthcare · Biotechnology · listed on NASDAQ
- Revenue, FY2025
- $14.3B
- Growth, 3 years a year
- 9.6%
- Cash margin
- 28%
- Net cash
- $5.9B
- Shares, 3-year change
- −4.3%
- Dividend yield
- 0.4%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.